{"text": "rt AT_USER $mrk says there were no lab abnormalities in the all oral dosing arms (e.g. alt). will have details @ 5pm london time.\u2026"}
{"text": "$mrk to continue to fade and fill in the gap"}
{"text": "rt AT_USER $mrk says there were no lab abnormalities in the all oral dosing arms (e.g. alt). will have details @ 5pm london time.\u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER $mrk hep c numbers could rise dramatically over next few years. they started a one pill, once per day trial this week.\u2026"}
{"text": "rt AT_USER $mrk hep c numbers could rise dramatically over next few years. they started a one pill, once per day trial this week.\u2026"}
{"text": "rt AT_USER $mrk hep c numbers could rise dramatically over next few years. they started a one pill, once per day trial this week.\u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER $mrk says there were no lab abnormalities in the all oral dosing arms (e.g. alt). will have details @ 5pm london time.\u2026"}
{"text": "rt AT_USER $mrk says there were no lab abnormalities in the all oral dosing arms (e.g. alt). will have details @ 5pm london time.\u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER $mrk says there were no lab abnormalities in the all oral dosing arms (e.g. alt). will have details @ 5pm london time.\u2026"}
{"text": "$mrk $gild rt AT_USER no doubt $abbv is looking like #3 combo, lots of drug interactions, but in the end price will drive the train"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "watch idea - gappers: $fb $yzc $rad $mrk $ebay $bbby $bhp $impv $armh #stocks #trading #options  -r"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "$mrk gilead sciences, inc. (nasdaq:gild) to face completion from merck &amp; co ... #mrk URL"}
{"text": "rt AT_USER merck is in the race for next-generation hepatitis c regimen $mrk $gild $abbv $bmy $jnj URL"}
{"text": "our penny stock newsletter alerts gained 2,100% in 4 weeks! huge news: URL #breakout $insy $mrk"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
{"text": "rt AT_USER new hep c data from $mrk are excellent: 1 pill/once per day cures 98% of patients. analysts' estimates likely to rise \u2026"}
